Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

BioMarin Pharmaceutical

Tracked across 4 events · 24 articles · First seen Apr 17, 2026 · Last active Sep 02, 2026

Sentiment
45
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 50
Business
Impact: BioMarin is the lead developer of the ASO medicine, leveraging its genetic medicine expertise. The collaboration could strengthen its pipeline and market position in rare diseases.
Jul 27, 2026 · 6 articles
4 60
Business
Impact: BioMarin is the acquirer, completing the purchase of Alesta to add ALE1 to its skeletal conditions portfolio. The deal strengthens its rare disease pipeline and aligns with its strategy, though it will be modestly dilutive to 2026 earnings.
Aug 19, 2026 · 6 articles
4 60
Business
Impact: BioMarin grants a license and receives royalties, ending costly litigation and providing a new revenue stream, though it loses some exclusivity rights.
Aug 31, 2026 · 6 articles
2 10
Tech
Impact: BioMarin Pharmaceutical is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track BioMarin Pharmaceutical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.